Key Market Segments:
By Product Type
-
Reagents & Kits
-
Instruments/Analyzers
-
Consumables & Accessories
-
Software
-
Services
By Radioisotope
-
Iodine-125
-
Cobalt-60
-
Indium-111
-
Tritium
-
Other Radioisotopes
By Application
-
Endocrinology
-
Oncology
-
Toxicology
-
Drug Testing & Pharmacokinetics
-
Clinical Diagnostics
By End User
-
Hospitals
-
Clinical Laboratories
-
Research & Academic Institutes
-
Pharmaceutical & Biotechnology Companies
-
Contract Research Organizations
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated with 36% revenue share in 2025, attributed to advanced diagnostic infrastructure, high RIA adoption, and strong healthcare expenditure.
Reagents & Kits led the Radioimmunoassay Market, owing to their essential role, reproducibility, cost-effectiveness, and wide application in diagnostics and research.
Growth is driven by rising prevalence of endocrine disorders, cancers, chronic diseases, and increasing adoption of automated, precise RIA systems.
The market was valued at USD 1.20 billion in 2025, supported by growing clinical and research laboratory adoption of RIA systems.
The market is projected to grow at a CAGR of 4.89% from 2026–2033, driven by rising demand for sensitive diagnostics globally.